Literature DB >> 28219222

[Relative analysis of platelet activation with bleeding risk in patients with primary immune thrombocytopenia].

M E Lyu1, Y Li, C C Lyu, W J Liu, Y Guan, S X Wang, R C Yang.   

Abstract

Objective: To study the relationship between platelet activation and the degree of bleeding in patients with primary immune thrombocytopenia (ITP) .
Methods: 43 patients with ITP were assessed based on ITP-BAT bleeding grading system. Platelet membrane glycoproteins (GP) Ⅰb, GPⅡb/Ⅲa and P-selectin expression were detected by flow cytometry analysis with and without adenosine diphosphate (ADP) stimulation. Association of platelet activation with platelet count, immature platelet fraction (IPF) , bleeding severity were evaluated.
Results: GPⅡb/Ⅲa and P-selection expressions on unstimulated platelet in ITP patients were higher than those in healthy controls (65.69±10.73 vs 7.16±0.99, t=4.130, P<0.001; 15.43±1.41 vs 12.55±1.03, t=2.070, P=0.043, respectively) , and GPⅠb expression was lower than that in healthy controls (240.11±24.93 vs 295.11±22.15, t=2.417, P=0.020) . Comparatively to healthy individuals, following ADP stimulation, GPⅡb/Ⅲa expression in ITP patients increased (133.96±12.17 vs 39.67±4.99, t=5.256, P<0.001) , whereas GPⅠb and P-selection expressions decreased (37.09±3.94 vs 109.77±23.66, t=3.901, P<0.001; 149.06±19.14 vs 205.73±21.00, t=2.070, P=0.043, respectively) . ADP-stimulated GPⅠb, ADP-stimulated and unstimulated P-selection, proportion of GPⅠb, P-selection levels with/without ADP stimulation were significantly associated with platelet counts (P<0.05) . ADP-stimulated P-selection and proportion of P-selection levels with/without ADP stimulation were significantly associated with IPF (P<0.05) . There were significant differences in the expressions of unstimulated P-selection, ADP-stimulated P-selection, ADP-stimulated GPⅠb stratified by bleeding grades (P<0.05) . The ratios of P-selection, GPⅡb/Ⅲa and GPⅠb with/without ADP stimulation in ITP patients were significantly different among various bleeding grades (P<0.05) . Higher proportion of GPⅠb with/without ADP stimulation was associated with higher risk of bleeding (OR=3.05, P=0.011) . Lower proportion of GPⅡb/Ⅲa and P-selection with/without ADP was associated with higher risk of bleeding (OR=0.32, P=0.023; OR=0.04, P=0.006, respectively) .
Conclusion: Platelet activation index could accurately assess the degree of bleeding in patients with ITP, and also be used as the observation index and reference index for treatment.

Entities:  

Keywords:  Hemorrhage; P-selectin; Platelet activation; Platelet membrane glycoprotein; Thrombocytopenia

Mesh:

Substances:

Year:  2017        PMID: 28219222      PMCID: PMC7348401          DOI: 10.3760/cma.j.issn.0253-2727.2017.01.007

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN: 0253-2727


原发免疫性血小板减少症(ITP)是最为常见的良性出血性疾病。ITP患者血小板数量减少与出血严重程度并不完全相关。虽然血小板计数低于20×109/L时患者更可能出现严重出血,但有些血小板计数高于20×109/L的患者仍有出血表现,而有些血小板计数极低的患者却无出血表现。因此,ITP患者出血程度不能单独用血小板计数解释。我们前期研究结果显示血小板聚集功能与ITP患者出血程度相关[1],我们推测血小板活化状态与ITP患者的出血程度相关。本研究中,我们采用流式细胞术检测ITP患者血小板膜糖蛋白(GP)Ⅰb、GPⅡb/Ⅲa和P选择素表达,探讨血小板活化和出血程度之间的关系。

病例与方法

1.研究对象:2014年12月至2015年3月于中国医学科学院血液病医院门诊或住院治疗的ITP患者43例纳入研究。男21例,女22例;中位年龄44(18~68)岁,中位PLT 15(2~99)×109/L。参照文献[2]标准进行诊断。以20名健康志愿者作为正常对照组,男8名、女12名,中位年龄41(22~65)岁,中位PLT 183(118~238)×109/L。本研究经医院伦理委员会批准,患者均知情同意。 2.出血评分方法:运用2013年ITP国际工作组(IWG)制定的ITP特异性出血评价工具(ITP-BAT)1.0版[3]对患者进行出血评分,出血症状包括皮肤(S)、黏膜(M)、器官(O)三项指标,得出SMO评分值,用SMO评分值界定不同程度的临床出血情况,严重出血(影响生命体征):O≥3;大量出血:M≥3;中度出血:S=3、M=2、O=2;轻度出血:S<3、M=1、O=1;无症状:S=0、M=0、O=0。由2名血液科医师完成所有ITP患者的出血评分。 3.标本采集:抽取ITP患者肘静脉血2~4 ml,取2 ml全血加入EDTA抗凝管,用于未成熟血小板比例(IPF)测定;取全血1 ml加入枸橼酸钠抗凝管,用于流式细胞术测定GPⅠb、GPⅡb/Ⅲa、P选择素。正常对照组同法采集外周静脉血标本。 4.流式细胞术检测血小板GPⅠb、GPⅡb/Ⅲa、P选择素表达水平:取1 ml枸橼酸钠抗凝血,轻轻混匀后静置,离心10 min(150×g)取富含血小板血浆,Falcon管内血小板计数用PBS调整至1×107/ml,加入20.0 µmol/L二磷酸腺苷(ADP),立即旋涡1 s混匀,室温24 °C,激活时间5 min[4]。CD61-PerCP(美国Biolegend公司产品)和侧向散射角双参数确定血小板群,实验管加入CD42b-APC(美国Biolegend公司产品)、CD62p-PE(美国Biolegend公司产品)、PAC-1-FITC(美国BD Biosciences公司产品),对照管加入同型对照IgG1抗体(美国Biolegend公司产品)和GPⅡb/Ⅲa受体拮抗剂(RGDS)(美国BD Biosciences公司产品),4 °C避光孵育45 min,PBS洗涤2次,最后加300 µl PBS重悬,上流式细胞仪检测。GPⅠb、GPⅡb/Ⅲa、P选择素的表达分别以CD42bPAC-1CD62p的平均荧光强度表示。 5.IPF测定:收集EDTA抗凝静脉血2 ml,在6 h内采用Sysmex XE-5000血液分析仪检测IPF(自动进行模式)。网织血小板中的RNA在网织红细胞通道内被核酸荧光染料染色,再用XE-pro IPF master软件根据荧光强度和前向角散射光强度在网织红细胞散点图上较高荧光强度的区域圈出网织血小板,通过分析得到IPF。 6.统计学处理:采用SPSS19.0进行数据分析。符合正态分布计量资料的组间比较采用t检验及配对t检验。各指标与出血分级之间的关系采用多元有序回归分析。采用二元回归法分析各指标与中度以上出血风险的相关性,计量资料间相关性采用Pearson线性相关分析。P<0.05为差异有统计学意义。

结果

1.ITP患者血小板活化指标:ITP患者激活前血小板GPⅠb表达低于正常对照组(t=2.417,P=0.020),GPⅡb/Ⅲa、P选择素表达高于正常对照组(t=4.130,P<0.001;t=2.070,P=0.043);ITP患者和正常对照组ADP激活后血小板P选择素、GPⅡb/Ⅲa表达均高于激活前(P<0.05),GPⅠb表达均低于激活前(P<0.05);ADP激活后ITP患者血小板GPⅡb/Ⅲa表达高于正常对照组(t=5.256,P<0.001),而P选择素和GPⅠb表达低于正常对照组(t=3.901,P<0.001;t=2.070,P=0.043)。ADP激活前后血小板GPⅡb/Ⅲa和P选择素表达比值在ITP患者和正常对照组间差异有统计学意义[(2.58±1.21)%对(7.75±3.57)%,t=7.297,P<0.001;(2.97±2.19)%对(10.12±9.37)%,t=4.084,P<0.001];两组间GPⅠb表达比值差异无统计学意义[(0.79±0.59)%对(0.78±0.39)%,t=0.005,P=0.995]。ITP患者ADP激活前后血小板GPⅡb/Ⅲa、P选择素、GPⅠb表达比值和激活前表达呈负相关(P=0.001,r=−0.540;P=0.002,r=−0.524;P=0.010,r=−0.434)。详见表1。
表1

ITP患者ADP激活前后血小板活化指标GPⅠb、GPⅡb/Ⅲa和P选择素表达(平均荧光强度,±s)

组别例数GPⅠb
GPⅡb/Ⅲa
P选择素
ADP激活前ADP激活后PADP激活前ADP激活后PADP激活前ADP激活后P
ITP43240.11±24.93149.06±19.140.02265.69±10.73133.96±12.17<0.00115.43±1.4137.09±3.94<0.001
正常对照20295.11±22.15a205.73±21.00b0.0447.16±0.99c39.67±4.99d<0.00112.55±1.03e109.77±23.66f<0.001

注:ITP:原发免疫性血小板减少症;ADP:二磷酸腺苷;GP:血小板膜糖蛋白。与ITP组比较,at= 2.417,aP=0.020,bt= 2.070,bP=0.043,ct= 4.130,cP<0.001,dt= 5.256,dP<0.001,et= 2.070,eP=0.043,ft= 3.901,fP<0.001

注:ITP:原发免疫性血小板减少症;ADP:二磷酸腺苷;GP:血小板膜糖蛋白。与ITP组比较,at= 2.417,aP=0.020,bt= 2.070,bP=0.043,ct= 4.130,cP<0.001,dt= 5.256,dP<0.001,et= 2.070,eP=0.043,ft= 3.901,fP<0.001 2.ITP患者血小板活化指标与血小板计数、IPF的相关性:ITP患者中位IPF为21.1%(4.4%~44.7%),中位PLT为15(2~99)×109/L,血小板计数与IPF呈负相关(r=−0.475,P=0.011)。ADP激活后GPⅠb表达、ADP激活前P选择素表达、ADP激活后P选择素表达、ADP激活前后GPⅠb表达比值、P选择素表达比值与血小板计数显著相关(P<0.05),ADP激活后P选择素表达、ADP激活前后P选择素表达比值与IPF显著相关(P<0.05)。详见表2。
表2

ITP患者血小板GPⅠb、GPⅡb/Ⅲa、P选择素与血小板计数、未成熟血小板比例的相关性分析

血小板活化指标血小板计数
未成熟血小板比例
P相关系数P相关系数
ADP激活前GPⅠb表达0.7610.0570.354−0.182
ADP激活后GPⅠb表达0.024−0.4040.4680.143
ADP激活前后GPⅠb表达比值0.017−0.4240.0650.354
ADP激活前GPⅡb/Ⅲa表达0.174−0.2550.2070.151
ADP激活后GPⅡb/Ⅲa表达0.863−0.0320.5470.119
ADP激活前后GPⅡb/Ⅲa表达比值0.3240.0180.172−0.165
ADP激活前P选择素表达0.045−0.3780.8460.038
ADP激活后P选择素表达0.0020.5360.011−0.472
ADP激活前后P选择素表达比值<0.0010.6390.037−0.396

注:ITP:原发免疫性血小板减少症;ADP:二磷酸腺苷;GP:血小板膜糖蛋白

注:ITP:原发免疫性血小板减少症;ADP:二磷酸腺苷;GP:血小板膜糖蛋白 3.ITP患者血小板活化指标与出血程度的相关性:43例患者根据ITP-BAT评分结果进行出血分级:无症状12例,轻度出血16例,中度出血9例,大量及严重出血6例。血小板计数、IPF在不同出血程度之间差异均有统计学意义(P=0.001、P=0.020)。 ADP激活前血小板P选择素表达在不同出血程度患者之间差异有统计学意义(P=0.040)(表3)。中度以上出血患者血小板P选择素表达高于轻度出血和无症状患者(20.20±8.54对13.16±6.57,t=2.526,P=0.017)。ADP激活后血小板P选择素、GPⅠb表达在不同出血程度患者之间差异有统计学意义(P=0.006、P=0.001)(表3)。中度以上出血患者ADP激活后血小板P选择素表达低于轻度出血和无症状患者(25.6±9.27对42.56±24.27,t=2.802,P=0.009),而中度以上出血患者GPⅠb表达高于轻度出血和无症状患者(121.73±61.25对46.19±23.42,t=3.771,P=0.003)。
表3

ADP激活前后ITP患者血小板GPⅠb、GPⅡb/Ⅲa、P选择素表达与出血程度的相关性(平均荧光强度,±s)

组别例数GPⅠb
GPⅡb/Ⅲa
P选择素
ADP激活前ADP激活后ADP激活前ADP激活后ADP激活前ADP激活后
无症状12129.36±24.9441.97±6.8346.00±7.08129.36±24.9412.94±2.5454.52±9.27
轻度出血16116.39±20.4649.35±7.4545.83±5.72116.39±20.4613.33±1.7333.59±5.02
中度出血9126.38±28.26127.10±18.94121.55±39.43126.38±28.2619.71±3.8525.43±3.54
大量及严重出血692.03±35.04120.86±46.00109.20±54.8090.03±35.0421.33±2.1826.66±6.36

P0.6110.0010.0820.1090.0400.006

注:ITP:原发免疫性血小板减少症;ADP:二磷酸腺苷;GP:血小板膜糖蛋白

注:ITP:原发免疫性血小板减少症;ADP:二磷酸腺苷;GP:血小板膜糖蛋白 4.ITP患者ADP激活前后血小板活化指标比值与出血程度的相关性:ADP激活前后ITP患者血小板P选择素、GPⅡb/Ⅲa、GPⅠb表达比值在不同出血程度患者之间差异有统计学意义(P=0.003、P=0.001、P=0.003)(表4)。中度以上出血患者ADP激活前后P选择素、GPⅡb/Ⅲa表达比值低于轻度出血和无症状患者[(1.51±1.01)%对(3.66±2.27)%,t=3.634,P=0.003;(1.36±0.62)%对(3.16±0.97)%,t=5.332,P<0.001)]。中度以上出血患者ADP激活前后GPⅠb表达比值高于轻度出血和无症状患者[(1.34±0.68)%对(0.53±0.29)%,t=3.568,P=0.006]。
表4

ADP激活前后ITP患者血小板GPⅠb、Ⅱb/Ⅲa及P选择素表达(平均荧光强度)比值与出血程度的相关性(%,±s)

组别例数GPⅠbGPⅡb/ⅢaP选择素
无症状120.44±0.243.40±1.044.74±2.43
轻度出血160.59±0.322.98±0.922.84±1.85
中度出血91.37±0.731.27±0.601.62±1.19
大量及严重出血61.25±0.701.56±0.721.22±0.37

P0.0030.0010.003

注:ITP:原发免疫性血小板减少症;ADP:二磷酸腺苷;GP:血小板膜糖蛋白

注:ITP:原发免疫性血小板减少症;ADP:二磷酸腺苷;GP:血小板膜糖蛋白 5.ITP患者血小板活化指标与中度以上出血风险的相关性:与出血程度相关的因素包括:ADP激活后GPⅠb表达,ADP激活前P选择素表达,ADP激活后P选择素表达,ADP激活前后GPⅠb、P选择素、GPⅡb/Ⅲa表达比值。评估这些指标与中度以上出血风险的相关性,结果显示:ADP激活前后GPⅠb表达比值是ITP患者中度以上出血的正性影响因素[OR=3.05(95% CI 1.29~7.24),P=0.011];ADP激活前后P选择素、GPⅡb/Ⅲa表达比值是ITP患者中度以上出血的负性影响因素[OR=0.32(95% CI 0.12~0.85),P=0.023;OR=0.04(95% CI 0~0.39), P=0.006]。

讨论

ITP患者出血的严重程度与血小板计数减少并非呈正相关,有的患者血小板计数尽管很低但不出血或出血并不严重。我们最近的临床研究发现ITP患者外周血IPF和血小板聚集功能与患者出血程度相关,提示血小板功能在ITP患者出血过程中发挥一定的作用[1]。本研究进一步证实了血小板活化状态与ITP患者出血情况存在相关性。 血小板的黏附、聚集和活化功能在血小板止血过程中起重要作用,其功能发挥均依赖其表面膜糖蛋白功能而实现。血小板表面GPⅠb-Ⅸ、GPⅡb/Ⅲa、P选择素均参与了血小板的聚集、活化和黏附功能,反映了体内血小板的功能及活化状态。PAC-1(血小板糖蛋白Ⅱ b/Ⅲa受体)是血小板活化时GPⅡb/Ⅲa暴露的纤维蛋白原结合位点。P选择素在血小板活化时随着颗粒内容物的释放而与质膜融合,能持久地存在于活化血小板表面。GPⅠb在血小板活化后由膜表面进入开放管道系统或裂解,使其表达水平降低[5]。本研究结果显示ITP患者外周血中血小板膜表面P选择素和GPⅡb/Ⅲa表达增高、GPⅠb表达减低,提示ITP患者血小板内在活性增高,其促凝功能增强。Olsson等[6]研究显示,ITP患者自身抗体可以通过Fc依赖的形式与血小板上FcgRⅡ受体结合而诱导血小板活化信号或通过Fc非依赖形式促进血小板活化。另外,ITP出血患者血管内皮损伤后胶原暴露也可导致血小板活化[7]。我们进一步研究发现ITP患者和正常对照ADP激活后血小板P选择素和GPⅡb/Ⅲa表达增高、GPⅠb表达减低,但是ADP激活前后ITP患者血小板GPⅡb/Ⅲa和P选择素表达比值低于正常对照组;ITP患者ADP激活前后P选择素、GPⅡb/Ⅲa、GPⅠb表达比值均与激活前表达水平呈负相关,以上结果提示ITP患者血小板经体外ADP诱导后的活化反应明显减弱,激活前血小板P选择素、GPⅡb/Ⅲa表达越高或GPⅠb表达越低,经ADP诱导后的活化反应越弱,推测原因:①ITP患者血小板表面P选择素、GPⅡb/Ⅲa、GPⅠb表达异常,说明ITP患者体内血小板已经处于活化状态,且接近活化界值,对于体外ADP刺激活化的反应减弱[4]。②P选择素、GPⅡb/Ⅲa、GPⅠb表达异常的血小板其表面ADP受体和ADP下游凝血酶信号途径抑制,导致ADP激活反应减弱[8]。 本研究结果显示ITP患者激活前血小板P选择素表达与血小板计数呈负相关,与Panzer等[9]研究结果一致,提示血小板胞质内的颗粒膜糖蛋白P选择素暴露在膜表面作为一种代偿机制,以减少因血小板数目少而发生出血的风险。Psaila等[10]研究认为血小板对ADP的反应不受血小板计数的影响,但我们研究发现ADP激活后GPⅠb、P选择素表达与血小板计数相关,具体原因有待进一步研究。 ITP患者IPF增高,反映了ITP患者血小板生成能力代偿性增加,未成熟血小板在外周血中发挥止血作用[1]。血小板完全活化后会发生构象变化,导致膜表面出现GPⅠb-Ⅸ、GPⅡb/Ⅲa变化,我们研究发现IPF与GPⅡb/Ⅲa、GPⅠb表达无相关性,而与P选择素表达相关,说明成熟血小板较未成熟血小板活化后更容易发生构象改变,可能因为未成熟血小板代偿性通过增加膜表面P选择素来增强血小板功能,导致构象改变能力减弱[8]。 本研究中ITP患者激活前血小板P选择素表达和出血程度相关,而GPⅡb/Ⅲa、GPⅠb表达与出血程度无相关,与van Bladel等[11]研究结果一致。分析原因:①严重出血患者通过增加血小板聚集、活化和黏附功能发挥止血作用。完全活化的血小板膜表面表达P选择素和GPⅡb/Ⅲa,通常分布于血管壁周围以保持血管完整性,外周血循环较少。②血小板完全活化后发生的构象变化不是持续的,很快就恢复静息状态,而血小板可以继续吸附血浆中脱落的P选择素[8]。中度以上出血患者与轻度出血和无症状患者比较,ADP激活后血小板表面GPⅠb、P选择素表达及ADP激活前后P选择素、GPⅡb/Ⅲa、GPⅠb表达比值的差异均有统计学意义,提示出血较重患者体外ADP诱导的血小板活化反应减弱,可能的原因:①出血较重患者因出血量大和血小板严重减少导致体内血小板代偿性的过度活化,体外对激活剂反应减弱。②出血较重患者体内高滴度抗体和炎症因子干扰了血小板的功能[12]。我们通过回归分析发现ADP激活前后P选择素、GPⅠb、GPⅡb/Ⅲa表达比值与中度以上出血风险相关,P选择素、GPⅡb/Ⅲa表达比值越大严重出血风险减少,GPⅠb表达比值越大严重出血风险增加,进一步证实ITP患者血小板体外活化功能缺陷、血小板黏附和聚集代偿性增强能力的减弱与出血程度相关。 本研究结果初步表明,血小板活化指标能比较准确地反映ITP患者出血程度,可以作为干预和疗效观察指标。本研究病例数较少,血小板活化指标对于ITP患者出血风险的预测价值尚需进一步临床研究加以验证。
  10 in total

1.  Agonist-inducible platelet activation in chronic idiopathic autoimmune thrombocytopenia.

Authors:  Simon Panzer; Lisa Höcker; Miriam Rieger; Rainer Vormittag; Daniela Koren; Daniela Dunkler; Ingrid Pabinger
Journal:  Eur J Haematol       Date:  2007-07-26       Impact factor: 2.997

2.  [Consensus of Chinese experts on diagnosis and treatment of adult primary immune thrombocytopenia (version 2012)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2012-11

3.  Flow cytometric evaluation of platelet activation in chronic autoimmune thrombocytopenia.

Authors:  Simon Panzer; Lisa Höcker; Rainer Vormittag; Miriam Rieger; Daniela Koren; Daniela Dunkler; Ingrid Pabinger
Journal:  Pediatr Blood Cancer       Date:  2006-10-15       Impact factor: 3.167

4.  Effect of steroids on the activation status of platelets in patients with Immune thrombocytopenia (ITP).

Authors:  Preeti Bhoria; Saniya Sharma; Neelam Varma; Pankaj Malhotra; Subhash Varma; Manni Luthra-Guptasarma
Journal:  Platelets       Date:  2014-03-11       Impact factor: 3.862

5.  Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia.

Authors:  B Psaila; J B Bussel; A L Frelinger; B Babula; M D Linden; Y Li; M R Barnard; C Tate; E J Feldman; A D Michelson
Journal:  J Thromb Haemost       Date:  2011-11       Impact factor: 5.824

6.  Functional platelet defects in children with severe chronic ITP as tested with 2 novel assays applicable for low platelet counts.

Authors:  Esther R van Bladel; Annemieke G Laarhoven; Laila B van der Heijden; Katja M Heitink-Pollé; Leendert Porcelijn; C Ellen van der Schoot; Masja de Haas; Mark Roest; Gestur Vidarsson; Philip G de Groot; Marrie C A Bruin
Journal:  Blood       Date:  2014-01-02       Impact factor: 22.113

7.  Serum from patients with chronic idiopathic thrombocytopenic purpura frequently affect the platelet function.

Authors:  Anna Olsson; P O Andersson; Lilian Tengborn; Hans Wadenvik
Journal:  Thromb Res       Date:  2002-08-15       Impact factor: 3.944

8.  In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation.

Authors:  Bethan Psaila; James B Bussel; Matthew D Linden; Bracken Babula; Youfu Li; Marc R Barnard; Chinara Tate; Kanika Mathur; Andrew L Frelinger; Alan D Michelson
Journal:  Blood       Date:  2012-01-31       Impact factor: 22.113

9.  Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group.

Authors:  Francesco Rodeghiero; Marc Michel; Terry Gernsheimer; Marco Ruggeri; Victor Blanchette; James B Bussel; Douglas B Cines; Nichola Cooper; Bertrand Godeau; Andreas Greinacher; Paul Imbach; Mehdi Khellaf; Robert J Klaassen; Thomas Kühne; Howard Liebman; Maria Gabriella Mazzucconi; Adrian Newland; Ingrid Pabinger; Alberto Tosetto; Roberto Stasi
Journal:  Blood       Date:  2013-01-29       Impact factor: 22.113

10.  [Application of immature platelet fraction absolute immature platelet fraction and thrombelastograph on assessment of bleeding risk in patients with immune thrombocytopenia].

Authors:  Ming'en Lyu; Yang Li; Feng Xue; Xiaofan Liu; Wenjie Liu; Tiantian Sun; Cuicui Lyu; Rongfeng Fu; Lei Zhang; Renchi Yang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2015-09
  10 in total
  1 in total

1.  Heterogeneity of Integrin αIIbβ3 Function in Pediatric Immune Thrombocytopenia Revealed by Continuous Flow Cytometry Analysis.

Authors:  Alexey A Martyanov; Daria S Morozova; Maria A Sorokina; Aleksandra A Filkova; Daria V Fedorova; Selima S Uzueva; Elena V Suntsova; Galina A Novichkova; Pavel A Zharkov; Mikhail A Panteleev; And Anastasia N Sveshnikova
Journal:  Int J Mol Sci       Date:  2020-04-25       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.